Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal RSVpreF vaccine phase 3 trial for prevention of RSV illness in infants
PACTR202101800162440Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing RSVpreF with Placebo (2 arms). Started Jun 2020; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on PACTR202101800162440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202101800162440.